thanx dr.Khalaf
and now..let us suggest the ways that could help women that have ectopic
pregnancy
like this(related to the picture above)
number a :the suggestion................................
b.........
c....
etc......
thanx dr.Khalaf
and now..let us suggest the ways that could help women that have ectopic
pregnancy
like this(related to the picture above)
number a :the suggestion................................
b.........
c....
etc......
there are three options
1- management expectant
2- medical by mtx
3- surgery
إلى شبيبة الأولى اللي ما بيعرفوا شو الmtx إليكم هذا المقال.
Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
BACKGROUND: Patients with ectopic pregnancy (EP) and low serum hCG concentrations and women with a pregnancy of unknown location (PUL) and plateauing serum hCG levels are commonly treated with systemic methotrexate (MTX). However, there is no evidence that treatment in these particular subgroups of women is necessary as many of these early EPs may resolve spontaneously. The aim of this study is whether expectant management in women with EP or PUL and with low but plateauing serum hCG concentrations is an alternative to MTX treatment in terms of treatment success, future pregnancy, health related quality of life and costs. METHODS/DESIGN: A multicentre randomised controlled trial in The Netherlands. Hemodynamically stable patients with an EP visible on transvaginal ultrasound and a plateauing serum hCG concentration < 1,500 IU/L or with a persisting PUL with plateauing serum hCG concentrations < 2,000 IU/L are eligible for the trial. Patients with a viable EP, signs of tubal rupture/abdominal bleeding, or a contra-indication for MTX will not be included. Expectant management is compared with systemic MTX in a single dose intramuscular regimen (1 mg/kg) in an outpatient setting. Serum hCG levels are monitored weekly; in case of inadequately declining, systemic MTX is installed or continued. In case of hemodynamic instability and/or signs of tubal rupture, surgery is performed. The primary outcome measure is an uneventful decline of serum hCG to an undetectable level by the initial intervention. Secondary outcomes are (re)interventions (additional systemic MTX injections and/or surgery), treatment complications, health related quality of life, financial costs, and future fertility. Analysis is performed according to the intention to treat principle. Quality of life is assessed by questionnaires before and at three time points after randomisation. Costs are expressed as direct costs with data on costs and used resources in the participating centres. Fertility is assessed by questionnaires after 6, 12, 18 and 24 months. Patients' preferences will be assessed using a discrete choice experiment.
جميل.. شكراً لك..
ما هو المكان الأشيع بين هذه المواضع لتوضع الحمل الهاجر Ectopic pregnancy؟
أشيع هذه الأماكن هو حدوث الحمل في البوق..وبنسبة90%
وأكثرها خطراً الحمل الخلالي (في آخر جزء من البوق)والذي قد ينتهي باستئصال الرحم كاملاً...
شكرا
شكراً كتير برنس......الله يجزيك الخير
u r the best prince
مشكور ...
وما هي أعراض الحمل الهاجر ؟
إذا غلط يا ريت تصلحولي...
آلام في الناحية السفلية للبطن أو في البطن...
إضافة لحدوث نزف دموي من منطقة الانغراس تظهر بالإيكو..
شو في كمان؟؟؟
انقطاع الطمث
يعني انقطاع الطمث إضافة لما سبق وذكرته(آلام +نزف)
مشكور
أحلى برنس
ectopic pregnancy العرضي بالاعراض السابقة غير شائع جدا
ضع ببالك القاعدة التالية
ابقي تشخيص الحمل الهاجر ببالك عند اي سيدة بتفاعل حمل ايجابي
اي spoting او الم عند سيدة بسن النشاط التناسلي مهما كان مع تفاعل حمل +
هو حمل هاجر حتى يثبت العكس
شكرا للمعلومة
valuable
thanx dr.Khalaf
and now..let us suggest the ways that could help women that have ectopic
pregnancy
like this(related to the picture above)
number a :the suggestion................................
b.........
c....
etc......
help her for what???
there are three options
1- management expectant
2- medical by mtx
3- surgery
expectant managment
maybe i do not know how to create the best statment
this is my ability
thanx again dr.Khalaf
إلى شبيبة الأولى اللي ما بيعرفوا شو الmtx إليكم هذا المقال.
Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
BACKGROUND: Patients with ectopic pregnancy (EP) and low serum hCG concentrations and women with a pregnancy of unknown location (PUL) and plateauing serum hCG levels are commonly treated with systemic methotrexate (MTX). However, there is no evidence that treatment in these particular subgroups of women is necessary as many of these early EPs may resolve spontaneously. The aim of this study is whether expectant management in women with EP or PUL and with low but plateauing serum hCG concentrations is an alternative to MTX treatment in terms of treatment success, future pregnancy, health related quality of life and costs. METHODS/DESIGN: A multicentre randomised controlled trial in The Netherlands. Hemodynamically stable patients with an EP visible on transvaginal ultrasound and a plateauing serum hCG concentration < 1,500 IU/L or with a persisting PUL with plateauing serum hCG concentrations < 2,000 IU/L are eligible for the trial. Patients with a viable EP, signs of tubal rupture/abdominal bleeding, or a contra-indication for MTX will not be included. Expectant management is compared with systemic MTX in a single dose intramuscular regimen (1 mg/kg) in an outpatient setting. Serum hCG levels are monitored weekly; in case of inadequately declining, systemic MTX is installed or continued. In case of hemodynamic instability and/or signs of tubal rupture, surgery is performed. The primary outcome measure is an uneventful decline of serum hCG to an undetectable level by the initial intervention. Secondary outcomes are (re)interventions (additional systemic MTX injections and/or surgery), treatment complications, health related quality of life, financial costs, and future fertility. Analysis is performed according to the intention to treat principle. Quality of life is assessed by questionnaires before and at three time points after randomisation. Costs are expressed as direct costs with data on costs and used resources in the participating centres. Fertility is assessed by questionnaires after 6, 12, 18 and 24 months. Patients' preferences will be assessed using a discrete choice experiment.
شي حلو
من ثمرات الpubmed
الله يعطيهن العافية....صدقة جارية
شكرا
شكراً كتير ع الموضوع....مفيد كتير
جزاكم الله خيرا